Infusions of allogeneic natural killer cells as cancer therapy

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3390-3400

  Leung, Wing ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5' NUCLEOTIDASE; ABATACEPT; AZACITIDINE; CD16 ANTIGEN; CD19 ANTIBODY; CD33 ANTIGEN; CYCLOPHOSPHAMIDE; DASATINIB; FLUDARABINE; IMATINIB; INTERLEUKIN 2; JANUS KINASE 1; JANUS KINASE 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LENALIDOMIDE; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; RITUXIMAB; SHORT HAIRPIN RNA; SORAFENIB; SPIRONOLACTONE; SUNITINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DONOR SELECTION; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG MEGADOSE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; LEUKEMIA; LOW DRUG DOSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PURIFICATION; QUALITY CONTROL; REGULATORY MECHANISM; REVIEW; TUMOR CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; DONOR; GENETICS; HEALTH CARE QUALITY; IMMUNOLOGY; METABOLISM; MORTALITY; NEOPLASMS; PROCEDURES; PROGNOSIS; STANDARDS; TRANSPLANTATION;

ANIMALS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS; PROGNOSIS; QUALITY ASSURANCE, HEALTH CARE; RECEPTORS, KIR; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84903822347     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1766     Document Type: Review

References (96)

1. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62: 309-35.
2. Kiessling R, Klein E, Pross H, Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975;5: 117-21.
3. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector eel Is. Int J Cancer 1975;16: 230-9.
4. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975;16: 216-29.
5. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975;5: 112-7.
6. Valiante NM, Parham P. Natural killer cells, HLA class I molecules, and marrow transplantation. Biol Blood Marrow Transplant 1997;3: 229-35.
7. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295: 2097-100.
8. MacLennan IC, Connell GE, Gotch FM. Effector activating determinants on IgG. II. Differentiation of the combining sites for C1q from those for cytotoxic K cells and neutrophils by plasmin digestion of rabbits IgG. Immunology 1974;26: 303-10.
9. Liu D, Xu L, Yang F, Li D, Gong F, Xu T. Rapid biogenesis and sensitization of secretory lysosomes in NK cells mediated by target-cell recognition. Proc Natl Acad Sei U S A 2005;102: 123-7.
10. + NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sei U S A 2010;108: 728-32.
11. Li S, Yan Y, Lin Y, Bullens DM, Rutgeerts O, Goebels J, et al. Rapidly induced, T-cell independent xenoantibody production is mediated by marginal zone B cells and requires help from NK cells. Blood 2007; 110: 3926-35.
12. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010;28: 57-78.
13. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med 1971;134: 1513-28.
14. Cudkowicz G, Stimpfling JH. Hybrid resistance to parental marrow grafts: association with the K region of H-2. Science 1964;144: 1339-40.
15. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319: 675-8.
16. Ljunggren HG, Karre K. In search of the 'missing self: MHC molecules and NK cell recognition. Immunol Today 1990;11: 237-44.
17. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995;268: 405-8.
18. D'Andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lanier LL. Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J Immunol 1995;155: 2306-10.
19. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, et al. Molecular clones of the p58 NK cell receptor reveal immuno-globulin-related molecules with diversity in both the extra- and intra-cellular domains. Immunity 1995;2: 439-49.
20. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol 2011;155: 14-29.
21. + T cells in human blood. J Immunol 2013;191: 1625-36.
22. Pyo CW, Guethlein LA, Vu Q, Wang R, Abi-Rached L, Norman PJ, et al. Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell lg-like receptor locus. PLoS ONE 2010;5: e15115.
23. Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013;13: 133-44.
24. Leung W, lyengar R, Triplett B, Turner V, Behm FG, Holladay MS, et al. Comparison of killer lg-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540-5.
25. Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, Tyan D, et al. Genetic control of human NK cell repertoire. J Immunol 2002;169: 239-47.
26. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatrie patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113: 3119-29.
27. Bari R, Bell T, Leung WH, Vong QP, Chan WK, Das Gupta N, et al. Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 2009;114: 5182-90.
28. Bari R, Leung M, Turner VE, Embrey C, Rooney B, Holladay M, et al. Molecular determinant-based typing of KIR alleles and KIR ligands. Clin Immunol 2011; 138: 274-81.
29. Bari R, Rujkijyanont P, Sullivan E, Kang G, Turner V, Gan K, et al. Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatrie allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2013;31: 3782-90.
30. Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002;63: 271-80.
31. Leung W, lyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004;172: 644-50.
32. Leung W, Handgretinger R, lyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007;97: 539-42.
33. Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009;15: 7330-4.
34. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010;70: 9554-61.
35. Koehl U, Brehm C, Huenecke S, Zimmermann SY, Kloess S, Bremm M, et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol 2013;3: 118.
36. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghau-sen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313: 1485-92.
37. lyengar R, Handgretinger R, Babarin-Dorner A, Leimig T, Otto M, Geiger TL, et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003;5: 479-84.
38. + T regulatory cells suppress NK cell-mediated mmunotherapy of cancer. J Immunol 2006;176: 1582-7.
39. Perez-Martinez A, lyengar R, Gan K, Chotsampancharoen T, Rooney B, Holladay M, et al. Blood dendriticcells suppress NK cell function and ncrease the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17: 598-607.
40. Shook DR, Leung W. Natural killer cell therapy for cancer: delivering on a promise. Transfusion 2013;53: 245-8.
41. Leung W, lyengar R, Leimig T, Holladay MS, Houston J, Handgretinger R. Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. Cancer Immunol Immunother 2005;54: 389-94.
42. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28: 955-9.
43. Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 2012;119: 5758-68.
44. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997;3: 177-82.
45. Moretta A, Ciccone E, Pantaleo G, Tambussi G, Bottino C, Melioli G, et al. Surface molecules involved in the activation and regulation of T or natural killer lymphocytes in humans. Immunol Rev 1989;111: 145-75.
46. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myelomappatients using GMP-compliant components. Blood 2008;111: 3155-62.
47. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69: 4010-7.
48. Denman CJ, Senyukov W, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012;7: e30264.
49. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106: 376-83.
50. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 2012;14: 830-40.
51. Tettamanti S, Magnani CF, Biondi A, Biagi E. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors. Immunol Lett 2013;155: 43-6.
52. Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer eel activation and killing of tumor cells. Cancer Res 2013;73: 1777-86.
53. Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 2009;15: 4857-66.
54. Esser R, Muller T, Stefes D, Kloess S, Seidel D. Gillies SD, et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 2012;16: 569-81.
55. Rujkijyanont P, Chan WK, Eldridge PW, Lockey T, Holladay M, Rooney B, et al. Ex vivo activation of CD56(+) immune cells that eradicate neuroblastoma. Cancer Res 2013;73: 2608-18.
56. Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood 2012;119: 5164-72.
57. Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, et al. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol 2012;3: 91.
58. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR, et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 2009;113: 6094-101.
59. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS ONE 2010;5: e9221.
60. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 2013;15: 1563-70.
61. Reed W, Noga SJ, Gee AP, Rooney CM, Wagner JE, McCullough J, et al. Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies. Transfusion 2009;49: 786-96.
62. Koepsell SA, Kadidlo DM, Fautsch S, McCullough J, Klingemann H, Wagner JE, et al. Successful "in-flight" activation of natural killer cells during long-distance shipping. Transfusion 2013;53: 398-403.
63. Leung W. Immunotherapy in acute leukemia. Semin Hematol 2009;46: 89-99.
64. Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011;2011: 379123.
65. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRllla gene. Blood 2002;99: 754-8.
66. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012;122: 1066-75.
67. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012;120: 4317-23.
68. Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012;120: 4324-33.
69. Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 × 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res 2013;19: 3844-55.
70. Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther 2012;11: 2674-84.
71. + tumor cells. Clin Cancer Res 2008;14: 4650-7.
72. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011;117: 1605-13.
73. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114: 379-88.
74. - NK cells from cord blood. Blood 2012;119: 6175-6.
75. Peng Y, Luo G, Zhou J, Wang X, Hu J, Cui Y, et al. CD86 is an activation receptorfor NK cell cytotoxicity against tumor cells. PLoS ONE 2013;8: e83913.
76. + tumors. Proc Natl Acad Sei U S A 2013;110: 14711-6.
77. Krusch M, Salih J, Schlicke M, Baessler T, Kampa KM, Mayer F, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 2009;183: 8286-94.
78. Schmiedel BJ, Arelin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 2011; 128: 2911-22.
79. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor val proie acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008;111: 1428-36.
80. Skov S, Pedersen MT, Andresen L, Strafen PT, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to hist one deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class l-related chain A and B. Cancer Res 2005;65: 11136-45.
81. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008;180: 163-70.
82. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006;66: 7317-25.
83. Leung WH, Vong QP, Lin W, Janke L, Chen T, Leung W. Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRgamma activation. J Exp Med 2013;210: 2675-92.
84. Bellucci R, Nguyen HN, Martin A, Heinrichs S, Schinzel AC, Hahn WC, et al. Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest 2012;122: 2369-83.
85. Klingemann HG. Cellular therapy of cancer with natural killer cells-where do we stand? Cytotherapy 2013;15: 1185-94.
86. Koepsell SA, Miller JS, McKenna DH Jr. Natural killer cells: a review of manufacturing and clinical utility. Transfusion 2013;53: 404-10.
87. Farnault L, Sanchez C, Baier C, Le Treut T, Costello RT. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol 2012; 2012: 421702.
88. Farhan S, Lee DA, Champlin RE, Ciurea SO. NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immu-notherapy 2012;4: 305-13.
89. Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33: 261-6.
90. Stern M, Passweg JR, Meyer-Monard S, Esser R, Tonn T, Soerensen J, et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013;48: 433-8.
91. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autolo-gous stem cell transplantation. Br J Haematol 2008;143: 641-53.
92. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected resultsto successful strategies. Nat Immunol 2008;9: 486-94.
93. Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mis-matched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011;118: 3273-9.
94. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adopt ivetransf er and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7.
95. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13: 98-107.
96. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 2010;59: 1739-44.